811 related articles for article (PubMed ID: 28821685)
21. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
Saishu Y; Yoshida T; Seino Y; Nomura T
J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
24. Relapsed Myasthenia Gravis after Nivolumab Treatment.
Mitsune A; Yanagisawa S; Fukuhara T; Miyauchi E; Morita M; Ono M; Tojo Y; Ichinose M
Intern Med; 2018 Jul; 57(13):1893-1897. PubMed ID: 29434145
[TBL] [Abstract][Full Text] [Related]
25. [Not Available].
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):263b. PubMed ID: 29176295
[No Abstract] [Full Text] [Related]
26. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
27. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
29. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.
Touat M; Maisonobe T; Knauss S; Ben Hadj Salem O; Hervier B; Auré K; Szwebel TA; Kramkimel N; Lethrosne C; Bruch JF; Laly P; Cadranel J; Weiss N; Béhin A; Allenbach Y; Benveniste O; Lenglet T; Psimaras D; Stenzel W; Léonard-Louis S
Neurology; 2018 Sep; 91(10):e985-e994. PubMed ID: 30089619
[TBL] [Abstract][Full Text] [Related]
31. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
[TBL] [Abstract][Full Text] [Related]
33. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
34. [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].
Reyes-Bueno JA; Rodriguez-Santos L; Serrano-Castro PJ
Rev Neurol; 2019 Apr; 68(8):333-338. PubMed ID: 30963530
[TBL] [Abstract][Full Text] [Related]
35. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
36. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.
Komatsu M; Hirai M; Kobayashi K; Hashidate H; Fukumoto J; Sato A; Usuda H; Tanaka K; Takahashi K; Kuwabara S
BMC Gastroenterol; 2021 Aug; 21(1):333. PubMed ID: 34445963
[TBL] [Abstract][Full Text] [Related]
37. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Hasegawa Y; Kawai S; Ota T; Tsukuda H; Fukuoka M
Immunotherapy; 2017 Aug; 9(9):701-707. PubMed ID: 28649876
[TBL] [Abstract][Full Text] [Related]
38. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
[TBL] [Abstract][Full Text] [Related]
39. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
40. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]